The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.
Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in DME Published in peer-reviewed journal Translational ...
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
Fintel on MSN11h
Citigroup Initiates Coverage of EyePoint Pharmaceuticals (EYPT) with Buy RecommendationFintel reports that on January 7, 2025, Citigroup initiated coverage of EyePoint Pharmaceuticals (NasdaqGM:EYPT) with a Buy ...
Global Bispecific Antibodies Market Size 2024: > USD 8.5 Billion Approved Bispecific Antibodies Yearly and Quarterly Sales ...
Adverum Biotechnologies, Inc. (NASDAQ:ADVM – Get Free Report) has received an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat ...
Citi has initiated coverage of EyePoint (EYPT) with a buy rating, stating it sees the company's drug Duravyu as well-positioned to compete in the wAMD market. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback